This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Promentis Pharmaceuticals Raises Nearly $3 Million In Series B Financing

MILWAUKEE, Jan. 21, 2014 /PRNewswire/ -- Promentis Pharmaceuticals, Inc., a specialty pharmaceutical company developing novel compounds for schizophrenia, Parkinson's disease and pediatric disorders including autism, announced today it has raised nearly $3 million in Series B financing. 

The company will utilize this funding to secure investigational new drug (IND) status for two of its lead compounds and advance these programs into human clinical testing over the next 24 months.  Black Horse Investments GmbH, located in Dusseldorf, Germany and headed by Patrick Schwarz-Schuette, led the round.  Additional investors included the Golden Angels Investors network and other private investors.

Chad Beyer, Ph.D., M.B.A., president and CEO of Promentis, stated, "We're encouraged by the extremely promising pre-clinical results we've witnessed in our advanced compounds.  Specifically, they have demonstrated the capacity to restore glutamatergic dysfunction and prevent oxidative damage, two key clinical symptoms of many central nervous system disorders."  

Klaus Veitinger, M.D., Ph.D., chairman of Promentis' board of directors, said, "We are pleased to have secured this funding and are eager to further advancing our lead molecules into the clinic.  It is our hope that our efforts will ultimately benefit patients suffering from devastating brain disorders."

Promentis' technology was in-licensed from Marquette University and the University of Wisconsin-Milwaukee.  In addition to these assets, the company has been successful in designing, synthesizing and characterizing its own proprietary molecules.

About Promentis Pharmaceuticals, Inc:

Promentis Pharmaceuticals, Inc. was founded in 2007 and is a private, emerging pharmaceutical company focused on developing unique compounds aimed at modifying brain chemistry for the treatment of schizophrenia and other central nervous system (CNS) disorders.  Support for Promentis' drug discovery and development programs, in part, has been provided by recent grants from the National Institute of Mental Health (NIMH) and the Michael J. Fox Foundation.  Additional information can be found at .

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs